Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



3 Humongous Health-Care Stocks This Week

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

While the Super Bowl isn't played until Sunday, the past week had several health-care stock champions. Here are three of the most humongous winners of the week.

Kick off with Keryx
Keryx Biopharmaceuticals (NASDAQ: KERX  ) scored big-time this week with its announcement of phase 3 results for kidney disease drug Zerenex. Shares soared nearly 100% before ending the week up more than 42%. 

The phase 3 study found that Zerenex helps lower phosphate levels in patients with end-stage renal disease, or ESRD. Because high phosphate levels can lead to serious health problems, these results were very encouraging. Additionally, the study showed that Zerenex reduced the need for ESRD patients to receive intravenous treatments to address iron deficiencies. 

Keryx's other big news of the week was a secondary share offering of $55 million. Actually, this news ties into the good news for Zerenex. The company moved ahead with the offering to raise cash for commercialization plans for the drug.

Get a little help from the rock
Shares of Sunesis Pharmaceuticals (NASDAQ: SNSS  ) jumped nearly 27% this week. Why? You won't find a clinical study result announcement, earnings release, or analyst upgrade that served as a catalyst. Nonetheless, there was some great news for Sunesis this week.

Huge investment firm Blackrock filed form SC 13G with the Securities and Exchange Commission on Wednesday. An SC 13G is required anytime an entity's ownership of a publicly traded company reaches 5%. What this means is that Blackrock has bought -- and perhaps is continuing to buy -- a much larger stake in Sunesis. As of last September, Blackrock owned less than 2% of the biotech. 

The attraction to Sunesis no doubt stems from the company's promising cancer drug vosaroxin. The drug is currently in two phase 3 trials targeting treatment of acute myeloid leukemia, or AML. Sunesis thinks vosaroxin could reach annual sales of $1 billion if it gains regulatory approval in the U.S. and Europe.

My hunch is that Blackrock views Sunesis as a prime acquisition target for a larger company in the not-too-distant future. Celgene (NASDAQ: CELG  ) could make a good fit. The booming biotech has a sales force in place for Vidaza but no longer has patent protection for the drug in the U.S.  

No need for alignment
Shares of Align Technologies (NASDAQ: ALGN  )  climbed more than 11% this week. The company reported solid earnings results on Wednesday.

Sales for its Invisalign dental alignment product were up nearly 10% in the fourth quarter, driving overall revenue up. Align's adjusted earnings of $0.27 per share easily beat analyst expectations of $0.22 per share.

The positive results yielded more good news for Align as well. Jefferies announced a buy rating for the stock with a $36 price target. That amount happens to exactly match the median price target for Align and represents a potential 13% upside.

Super champion
Which of this week's winners has the best chance to score the most in 2013? It just might be Sunesis. The company should announce interim safety results from its phase 3 VALOR trial of vosaroxin in June. If those results are positive, Sunesis could be a champion stock this year. As for that other competition being played on Sunday, I'll pick San Francisco by seven points. 

The Motley Fool's chief investment officer has selected his No. 1 stock for the year, but it's not any of our humongous stocks of the week. Find out which stock it is in our brand-new free report: "The Motley Fool's Top Stock for 2013." I invite you to take a copy, free for a limited time. Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2231524, ~/Articles/ArticleHandler.aspx, 9/28/2016 6:50:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 4:00 PM
ALGN $94.44 Up +1.35 +1.45%
Align Technology CAPS Rating: ****
KERX $5.17 Up +0.07 +1.37%
Keryx Biopharmaceu… CAPS Rating: **
SNSS $4.51 Up +0.12 +2.73%
Sunesis Pharmaceut… CAPS Rating: **
CELG $107.40 Up +1.09 +1.03%
Celgene CAPS Rating: *****